30
300347.SHE Hangzhou Tigermed Consulting
- Market cap
- CNY 42.9B
- P/E
- -
- P/B
- 2.16x
- ROE
- -1.8%
- Dividend yield
- 0.80%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 300347.SHE undervalued?
Graham numberThe Graham number of Hangzhou Tigermed Consulting cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Hangzhou Tigermed Consulting fundamental analysis
No fundamental analysis for Hangzhou Tigermed Consulting yet.
Hangzhou Tigermed Consulting stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Hangzhou Tigermed Consulting
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as …
Full company profileHangzhou Tigermed Consulting financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Hangzhou Tigermed Consulting annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.17B | 1.69B | 2.30B | 2.80B | 3.19B | 5.21B | 7.09B | 7.38B | 6.60B | 6.83B | 7.72B |
| Gross Profit | 447M | 724M | 992M | 1.30B | 1.51B | 2.27B | 2.81B | 2.85B | 2.24B | 1.87B | 2.11B |
| Operating Income | 199M | 417M | 596M | 1.08B | 2.22B | 3.70B | 2.58B | 2.49B | 664M | 667M | 894M |
| EBITDA | 258M | 474M | 684M | 1.17B | 2.35B | 3.83B | 2.83B | 2.80B | 1.02B | 1.42B | 894M |
| Net Income | 141M | 301M | 472M | 842M | 1.75B | 2.87B | 2.01B | 2.02B | 405M | 888M | -363M |
| EPS | 0.20 | 0.41 | 0.63 | 1.13 | 2.19 | 3.30 | 2.32 | 2.34 | 0.47 | 1.03 | -0.42 |
| Balance Sheet | |||||||||||
| Total Assets | 2.39B | 3.58B | 4.68B | 7.57B | 19.5B | 23.7B | 27.4B | 29.7B | 28.7B | 28.4B | 28.0B |
| Total Liabilities | 549M | 782M | 1.41B | 2.05B | 1.65B | 3.14B | 4.77B | 5.23B | 4.61B | 4.10B | 4.72B |
| Shareholders' Equity | 1.63B | 2.49B | 2.84B | 4.23B | 16.1B | 18.1B | 19.6B | 21.0B | 20.7B | 21.0B | 19.6B |
| Cash & Short-term Investments | 539M | 613M | 705M | 2.11B | 10.1B | 8.57B | 7.88B | 7.46B | 2.13B | 1.78B | 2.10B |
| Total Debt | 191M | 260M | 713M | 1.04B | 279M | 899M | 2.58B | 2.83B | 2.63B | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 192M | 315M | 522M | 528M | 999M | 1.42B | 1.36B | 1.15B | 1.10B | 1.12B | - |
| Capital Expenditure | 61.7M | 46.0M | 91.7M | 103M | 156M | 369M | 449M | 314M | 357M | 214M | 175M |
| Free Cash Flow | 130M | 269M | 431M | 425M | 842M | 1.06B | 909M | 837M | 740M | 904M | 854M |
| Ratios | |||||||||||
| ROE | 8.6% | 12.1% | 16.6% | 19.9% | 10.9% | 15.9% | 10.2% | 9.6% | 2.0% | 4.2% | -1.8% |
| ROA | 5.9% | 8.4% | 10.1% | 11.1% | 9.0% | 12.1% | 7.3% | 6.8% | 1.4% | 3.1% | -1.3% |
| Net Profit Margin | 12.0% | 17.8% | 20.5% | 30.0% | 54.8% | 55.1% | 28.3% | 27.4% | 6.1% | 13.0% | -4.7% |
| Debt to Equity | 0.12x | 0.10x | 0.25x | 0.25x | 0.02x | 0.05x | 0.13x | 0.13x | 0.13x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Hangzhou Tigermed Consulting dividends
- Dividend yield
- 0.80%
- Forward dividend
- 0.13 CNY
- Payout ratio
- 38.7%
- Ex-dividend date
- Jul 10, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 344M | 0.40 | 38.7% |
| 2024 | CNY 642M | 0.74 | 158.5% |
| 2023 | CNY 590M | 0.68 | 29.1% |
| 2022 | CNY 432M | 0.50 | 21.6% |
| 2021 | CNY 262M | 0.30 | 9.1% |
| 2020 | CNY 271M | 0.34 | 15.5% |
| 2019 | CNY 175M | 0.23 | 20.7% |
| 2018 | CNY 127M | 0.17 | 26.8% |
| 2017 | CNY 62.3M | 0.08 | 20.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on Jul 1, 2019.
Who owns Hangzhou Tigermed Consulting
- Insiders 32.53%
- Institutions 31.87%
- Public & others 35.60%
- Shares outstanding 732M
- Free float 592M
Hangzhou Tigermed Consulting company profile
- Company name
- Hangzhou Tigermed Consulting
- Ticker
- 300347.SHE
- ISIN
- CNE100001KV8
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Aug 17, 2012
- Sector
- Healthcare
- Industry
- Life Sciences Tools & Services
- Employees
- 11,130
- Fiscal year end
- December
- Address
- No. 508, Lujiatan Street, Hangzhou, China, 310051
- Phone
- 86 571 2888 7227
- Website
- tigermedgrp.com
About Hangzhou Tigermed Consulting
Hangzhou Tigermed Consulting Co., Ltd, together with its subsidiaries, provides contract research organization services in the People's Republic of China and internationally. The company offers clinical trial operation services, such as clinical pharmacology, registration and regulatory affairs, scientific affairs, medical translation, pharmacovigilance, real-world research, third-party auditing and training, etc. for innovative drugs, generic drugs, and medical devices, as well as supporting services directly related to clinical trials, including clinical operation, clinical trials, and clinical trials management. It also provides clinical trial related and laboratory services in the drug development process comprising data management and statistical analysis, clinical trial site management, subject recruitment, medical imaging, and laboratory services. In addition, the company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, decentralized clinical trials, clinical development strategy, site management, medical device/in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services. Further, it provides medical imaging, pharmacovigilance, medical translation, quality assurance, GMP and medical device consulting, central laboratories, functional services, recruitment management, EDC cloud-based system, and remote follow-up center services; and post-marketing clinical research solutions, such as site identification and selection, central monitoring, project team management, vendor management, and SAS project management services. Hangzhou Tigermed Consulting Co., Ltd was incorporated in 2004 and is headquartered in Hangzhou, the People's Republic of China.
Hangzhou Tigermed Consulting management
10- Dr. Xiaoping Ye D.Phil, EMBA, M.D., Ph.D.Co-Founder & Chairman · born 1963
- Mr. Zengyu WenPresident, GM & Executive Director · born 1980
- Mr. Hao WuCo- President · born 1967
- Dr. Xiaochun Cao M.D.Co-Founder & Executive Director · born 1969
- Ms. Chengcheng YangSVP & CFO · born 1974
- Ms. Xiao Ri LiSecretary · born 1983
- Mr. Yifei PengSenior VP & COO
- Dr. Tianrong Ji M.D., Ph.D.SVP & Chief Investment Officer
- Xiao Cui ChenAccounting Supervisor
- Mr. Song MengVP & Chief Technology Officer